SeraCare Life Sciences Inc, Milford, Mass, has launched multiplexed reference materials for use in inherited cancer testing by next-generation sequencing (NGS). The Seraseq inherited cancer DNA mix reference materials were developed with input from industry experts to validate the ability of synthetic reference materials to address technically challenging variants. Addressing the lack of multiplexed reference materials for targeted NGS assays, the materials are focused on seven genes associated with inherited cancer syndromes, including BRCA1 and BRCA2. The product combines more than 20 pathogenic variants of diverse types in a well-characterized genomic background that can be used for assay development and analytical validation. For more information, visit SeraCare.
